Retatrutide Dosage & Reconstitution: Research Protocol Guide

Research Disclaimer: Retatrutide is a research compound sold exclusively for in-vitro and laboratory use. Dosing information here is derived from published Phase 2 clinical trial protocols for reference purposes. This is not medical or clinical guidance. Retatrutide is not approved for human use.

Retatrutide (LY3437943) Phase 2 trials used weekly subcutaneous administration with a structured dose-escalation schedule starting at 2 mg/week and titrating to maintenance doses between 4 mg and 12 mg/week over 16–20 weeks. Understanding these escalation schedules — and how to calculate concentrations from lyophilized vials — is essential for structured research protocols.

This article covers the Phase 2 escalation schedule, reconstitution math for each available vial format, ready-to-inject pen formats, and storage requirements.

Table of Contents#

1. Phase 2 Dose-Escalation Schedules
2. Reconstitution: Volume Calculations
3. Available Vial and Pen Formats
4. Injection Volume Guide
5. Storage and Stability
6. Frequently Asked Questions
7. Key Research References

Phase 2 Dose-Escalation Schedules#

The retatrutide Phase 2 NEJM trial (Jastreboff et al., 2023) tested four maintenance doses: 1, 4, 8, and 12 mg/week. Each arm used a stepwise escalation to minimize GI adverse events. The escalation schedule used in the 8 mg and 12 mg arms:

The rationale for slow escalation is GLP-1/glucagon receptor–mediated nausea and vomiting, which attenuate significantly once the subject habituates to the dose. Rapid escalation to high doses significantly increases GI adverse event rate and discontinuation.

The lower-dose arm (4 mg maintenance) used a simpler 2-step escalation: 2 mg for 4 weeks, then 4 mg thereafter.

Working Doses in Research Literature#

The most studied maintenance dose with comprehensive outcome data is 8 mg/week — which produced 22.8% weight reduction at 48 weeks with a tolerability profile considered manageable in the Phase 2 population. The 12 mg arm produced 24.2% but with higher discontinuation. Most ongoing Phase 3 trials (TRIUMPH program) use 4 mg, 8 mg, and 12 mg arms with refined escalation.

Reconstitution: Volume Calculations#

Retatrutide lyophilized vials require reconstitution with bacteriostatic water (BAC water) prior to use. The target concentration determines how much BAC water to add per vial, and what volume to draw for each dose.

Standard Reconstitution Concentrations#

For a 10 mg vial:

For a 20 mg vial:

For a 30 mg vial:

Recommended approach: For precision and small injection volumes, the 10 mg/mL concentration (add 1 mL per 10 mg of lyophilized peptide) is preferred. Injection volumes of 0.4–1.2 mL per dose are compatible with standard 1 mL insulin syringes or dedicated peptide syringes.

Reconstitution Procedure#

1. Allow both the lyophilized vial and BAC water vial to reach room temperature before reconstitution.
2. Draw the calculated volume of BAC water into the syringe.
3. Insert needle into the lyophilized vial and inject BAC water slowly along the inside glass wall — do not inject directly onto the lyophilized cake.
4. Gently swirl (do not shake) until fully dissolved. The solution should be clear and colorless.
5. Label with compound, concentration, reconstitution date, and initials.
6. Transfer to refrigerator (2–8°C) immediately.

Available Vial and Pen Formats#

ZPHC manufactures retatrutide in several research formats to suit different protocol needs:

Lyophilized Vials#

• 5 mg vial — suitable for initial dose-escalation (2 mg/week weeks 1–4 = one vial for 2.5 weeks)
• 10 mg vial — standard single-use vial; ideal for 8 mg/week dosing (1 dose per vial with 2 mg margin)
• 15 mg vial — one vial covers one 12 mg dose with 3 mg margin
• 20 mg vial — 2–3 doses at 8 mg/week; 1 dose + next escalation step
• 30 mg vial — 3 doses at 10 mg/week or 2 doses at 12 mg/week

Multi-Dose Kits (ZPHC)#

• 5 × 10 mg vials — 50 mg total; supports a complete 8 mg/week 4-week run or escalation schedule
• 5 × 12 mg vials (60 mg kit) — supports 5 weeks at 12 mg/week maintenance
• 10 × 10 mg vials (100 mg kit) — for 12-week research segments at 8 mg/week

Aqueous Pens (Ready-to-Inject)#

• 30 mg pen — pre-formulated in water for injection; no reconstitution required; use within stated shelf life after first use
• 60 mg pen — higher volume per pen; suited for longer single-pen protocols

Pens eliminate reconstitution error and BAC water dependency. They are the format closest to commercial GLP-1 pen designs.

Injection Volume Guide#

At 10 mg/mL concentration:

Subcutaneous injection sites used in clinical trials: abdomen (preferred for absorption consistency), upper thigh, upper arm. Rotate sites weekly to minimize local reactions.

Storage and Stability#

Lyophilized (unreconstituted) vials:

• Store at 2–8°C (refrigerator)
• Protect from light
• Do not freeze
• Shelf life: typically 24 months from manufacture when stored correctly

Reconstituted solution:

• Store at 2–8°C
• Stable for up to 28 days post-reconstitution with bacteriostatic water
• Do not freeze reconstituted solution
• Discard if solution becomes cloudy, colored, or contains particulate matter

Aqueous pens:

• Unopened: 2–8°C, protect from light
• In-use (opened): store at 2–8°C; use within 28 days or per manufacturer specification
• Never freeze

Bacteriostatic water (BAC water) contains benzyl alcohol as a preservative, which extends the post-reconstitution stability compared to sterile water for injection. For research protocols requiring more than 7 days of in-use storage, BAC water is strongly preferred.

Frequently Asked Questions#

What syringe should I use for retatrutide reconstitution? Standard 1 mL insulin syringes (U-100) work well for volumes between 0.1 and 1 mL. For doses requiring more than 1 mL (e.g., 12 mg at 5 mg/mL concentration = 2.4 mL), a 3 mL syringe with fine-gauge needle is appropriate.

Can I use sterile water instead of bacteriostatic water? Sterile water (water for injection, WFI) can be used but results in a multi-use vial without antimicrobial preservation. Use within 24 hours of reconstitution if bacteriostatic water is unavailable. BAC water is strongly recommended for any multi-use scenario.

How long is reconstituted retatrutide stable? With bacteriostatic water at 2–8°C and protected from light: 28 days is the commonly cited reference stability. Some formulations tested at 4°C show minimal degradation up to 42 days, but 28 days is the conservative working limit.

Does retatrutide need to be kept cold during shipping? Lyophilized peptides are more robust than solutions during transit. Brief room-temperature exposure during shipping (≤72 hours) does not meaningfully degrade lyophilized retatrutide. Once received, refrigerate immediately. Avoid repeated freeze-thaw cycles.

What does the reconstituted solution look like? Retatrutide reconstitutes to a clear, colorless solution. Any yellow tint, cloudiness, or visible particulates indicates degradation and the vial should not be used in research.

Key Research References#

1. Jastreboff AM, et al. "Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." NEJM. 2023;389(6):514–526.
2. Coskun T, et al. "LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept." Cell Metab. 2022;34(9):1234–1247.
3. Frías JP, et al. "Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes." NEJM. 2021;385(6):503–515.